{"schema_version":"1","generated_at":"2026-10-29T07:41:56.995Z","data_as_of":null,"url":"https://www.findmykol.com/kol/christopher-sweeney","json_url":"https://www.findmykol.com/kol/christopher-sweeney/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"christopher-sweeney","name":"Christopher Sweeney","credential":"MD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"Boston","state":"MA","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1659337038"},"summary":"Christopher Sweeney is an Oncology physician. ClinicalTrials.gov lists 9 registered studies matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"note":"Research metrics are not shown for this record: either no confident publication match for this name, or more than one clinician shares the matched author record."},"trials":{"count":9,"shown":3,"withheld":6,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT04495179","title":"A Study of AZD4635 With Durvalumab and With Cabazitaxel and Durvalumab in Patients With mCRPC.","phase":"PHASE2","status":"COMPLETED","role":"Overall official","sponsor":"AstraZeneca","source_url":"https://clinicaltrials.gov/study/NCT04495179","trial_url":"https://www.findmykol.com/trial/NCT04495179"},{"nct":"NCT04136353","title":"Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","role":"Overall official","sponsor":"University of Sydney","source_url":"https://clinicaltrials.gov/study/NCT04136353","trial_url":"https://www.findmykol.com/trial/NCT04136353"},{"nct":"NCT02446405","title":"Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer","phase":"PHASE3","status":"ACTIVE_NOT_RECRUITING","role":"Overall official","sponsor":"University of Sydney","source_url":"https://clinicaltrials.gov/study/NCT02446405","trial_url":"https://www.findmykol.com/trial/NCT02446405"}],"source":"trials"},"payments":{"company_count":8,"program_years":{"first":2021,"last":null},"rows_total":11,"shown":3,"withheld":8,"rows":[{"payer":"PFIZER INC.","program_year":2023,"amount_usd":105.04,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1659337038"},{"payer":"Bayer HealthCare Pharmaceuticals Inc.","program_year":2022,"amount_usd":12612.5,"payment_count":3,"source_url":"https://openpaymentsdata.cms.gov/search?query=1659337038"},{"payer":"E.R. Squibb & Sons, L.L.C.","program_year":2022,"amount_usd":2080,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1659337038"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1659337038","source":"payments"},"prescribing":{"data_year":2023,"areas_total":2,"areas_shown":2,"areas":[{"area":"Cancer & immunology","share_pct":88.9,"classes_total":5,"classes":[{"class":"Anti-androgens","setting":"prescribed","share_pct":29.4,"drugs":[{"name":"Nubeqa","share_pct":57.8},{"name":"Erleada","share_pct":42.2}],"max_beneficiaries":null},{"class":"Cytochrome P450 17A1 Inhibitor","setting":"prescribed","share_pct":21.6,"drugs":[{"name":"Abiraterone Acetate","share_pct":100}],"max_beneficiaries":11}]},{"area":"Metabolism & gastrointestinal","share_pct":11.1,"classes_total":1,"classes":[{"class":"Corticosteroid","setting":"prescribed","share_pct":11.1,"drugs":[{"name":"Prednisone","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2022,"office_pct":0,"facility_pct":100},"source":"medicare"},"funding":{"award_count":4,"fiscal_years":{"first":2011,"last":2022},"rows_total":10,"shown":3,"withheld":7,"matched_by":"principal investigator name at an organization in the practice state","rows":[{"project":"R01CA238020","title":"Comprehensive genomic profiling of aggressive hormone sensitive prostate cancer","fiscal_year":2022,"amount_usd":"513517","organization":"DANA-FARBER CANCER INST","source_url":"https://reporter.nih.gov/quickSearch/R01CA238020"},{"project":"R01CA238020","title":"Comprehensive genomic profiling of aggressive hormone sensitive prostate cancer","fiscal_year":2021,"amount_usd":"577920","organization":"DANA-FARBER CANCER INST","source_url":"https://reporter.nih.gov/quickSearch/R01CA238020"},{"project":"R01CA238020","title":"Comprehensive genomic profiling of aggressive hormone sensitive prostate cancer","fiscal_year":2020,"amount_usd":"616230","organization":"DANA-FARBER CANCER INST","source_url":"https://reporter.nih.gov/quickSearch/R01CA238020"}],"source":"grants"},"contact":{"address_1":"44 BINNEY ST","address_2":"D1230","city":"Boston","state":"MA","zip":"021156013","phone":"617-632-4524","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1659337038","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":6,"payments":8,"funding":7}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2010-02-02","collected_at":"2026-10-27T00:00:00.000Z"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2023},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year"}},"methodology_url":"https://www.findmykol.com/about#methodology"}